Crossmark

Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)

Crossref DOI link: https://doi.org/10.1186/s40425-018-0367-1

Published Online: 2018-06-22

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Danaher, Patrick

Warren, Sarah https://orcid.org/0000-0001-9465-8636
Lu, Rongze

Samayoa, Josue

Sullivan, Amy

Pekker, Irena

Wallden, Brett

Marincola, Francesco M.

Cesano, Alessandra
Funding

Funding for this research was provided by:

not applicable
License Information

Text and Data Mining valid from 2018-06-22
More Information

Article History

Received: 2 March 2018

Accepted: 25 May 2018

First Online: 22 June 2018

Ethics approval and consent to participate

: Not applicable.

: P.D., S.W., A.S., I.P., B.W., and A.C. are employees and shareholders of NanoString Technologies. R.L, J.S., and F.M.M. are employees of AbbVie Biotherapeutics.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.